Latest GSK News & Updates

See the latest news and media coverage for GSK. We track all announcements, press releases, and industry mentions in real time, all in one place.

GSK

Global biopharmaceutical company

gsk.com

Headquarters: London, United Kingdom
Company type: Public company
Number of employees: 85,000+

Last updated Today

Latest news about GSK

In short: GSK expanded its oncology and respiratory pipelines through multi-billion dollar acquisitions and secured key regulatory milestones in liver health.

Company announcements

Yesterday GSK

GSK's Utebzi approved in US for complicated UTIs

It is the first oral carbapenem antibiotic, offering alternative to IV therapy for patients with limited oral options.

June 12 GSK

GSK's momelotinib received Orphan Drug Designations for VEXAS syndrome

The FDA and EMA granted the designations, supporting development for a rare life-threatening condition with no approved treatments.

June 9 GSK

GSK acquires Nuvalent for $10.6 billion

The deal includes two late-stage lung cancer drugs and is expected to be accretive from 2027.

May 28 GSK

GSK announces bepirovirsen achieves functional cure in hepatitis B trials

Pivotal B-Well data show 19% functional cure rate, 26% in lower viral activity, vs 0% for standard of care.

Media coverage

Yesterday Fierce Pharma

4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line

GSK and Spero Therapeutics have scored an FDA approval for Utebzi as the first oral carbapenem antibiotic for complicated urinary tract infections (cUTI). With the...

Yesterday Reuters

US FDA approves GSK s oral antibiotic for drug-resistant UTIs

, opens new tab oral antibiotic to treat complicated urinary tract infections, the regulator said on...

June 16 Law360

Judge Allows Pfizer, Moderna Defenses In GSK Vax IP Dispute - Law360

A Delaware federal judge on Tuesday permitted Pfizer and Moderna to move ahead with their arguments that GlaxoSmithKline patents the company claims are infringed by...

June 15 Seeking Alpha

Oppenheimer’s top buy ideas and sell ideas within each sector

Oppenheimer analysts remain bullish, citing beta and momentum, and offer buy/sell recommendations for each sector.

Never miss news about GSK

Track GSK and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

GSK competitors & trending companies

Browse news for competitors to GSK and other trending companies.